Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study
Zachery R. Reichert, Todd M. Morgan, Gerald Li, et al.
Annals of Oncology (2022) Vol. 34, Iss. 1, pp. 111-120
Open Access | Times Cited: 100

Showing 1-25 of 100 citing articles:

Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer
Nicolette M. Fonseca, Corinne Maurice‐Dror, Cameron Herberts, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 31
Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation
Christian Rolfo, Russell W. Madison, Lincoln W. Pasquina, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 11, pp. 2452-2460
Open Access | Times Cited: 19
Circulating tumor DNA validity and potential uses in metastatic breast cancer
Ottavia Amato, Nefeli Giannopoulou, Michail Ignatiadis
npj Breast Cancer (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 16
Circulating Tumor DNA—A Novel Biomarker of Tumor Progression and Its Favorable Detection Techniques
Xiaosha Wen, Huijie Pu, Quan Liu, et al.
Cancers (2022) Vol. 14, Iss. 24, pp. 6025-6025
Open Access | Times Cited: 39
Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer
Aleix Prat, Fara Brasó‐Maristany, Olga Martínez‐Sáez, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 33
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA
Jhanelle E. Gray, Myung‐Ju Ahn, Geoffrey R. Oxnard, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 17, pp. 3340-3351
Open Access | Times Cited: 31
Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation
Gian Marco Franceschini, Orsetta Quaini, Kei Mizuno, et al.
Cancer Discovery (2023) Vol. 14, Iss. 3, pp. 424-445
Open Access | Times Cited: 26
Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities
Xinan Wang, Giuseppe Lamberti, Alessandro Di Federico, et al.
Annals of Oncology (2024) Vol. 35, Iss. 6, pp. 508-522
Closed Access | Times Cited: 12
Targeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumors
Yoshiaki Nakamura, Hiroshi Ozaki, Makoto Ueno, et al.
Nature Medicine (2024)
Open Access | Times Cited: 12
Circulating tumor extracellular vesicles to monitor metastatic prostate cancer genomics and transcriptomic evolution
Irene Casanova‐Salas, Daniel Aguilar, Sarai Córdoba-Terreros, et al.
Cancer Cell (2024) Vol. 42, Iss. 7, pp. 1301-1312.e7
Open Access | Times Cited: 11
Assay Validation of Cell-Free DNA Shallow Whole-Genome Sequencing to Determine Tumor Fraction in Advanced Cancers
Micah Rickles-Young, Gabriel Tinoco, Junko Tsuji, et al.
Journal of Molecular Diagnostics (2024) Vol. 26, Iss. 5, pp. 413-422
Open Access | Times Cited: 9
Colorectal Cancer Recurrence Prediction Using a Tissue-Free Epigenomic Minimal Residual Disease Assay
Yoshiaki Nakamura, Yuichiro Tsukada, Nobuhisa Matsuhashi, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 19, pp. 4377-4387
Open Access | Times Cited: 8
A perspective review on the systematic implementation of ctDNA in phase I clinical trial drug development
Nolwen Guigal-Stéphan, Brian P. Lockhart, Tina Moser, et al.
Journal of Experimental & Clinical Cancer Research (2025) Vol. 44, Iss. 1
Open Access | Times Cited: 1
Circulating Tumor DNA in the Management of Early-Stage Breast Cancer
Katerina Vlataki, Sevastiani Antonouli, C. Kalyvioti, et al.
Cells (2023) Vol. 12, Iss. 12, pp. 1573-1573
Open Access | Times Cited: 18
Exploring the Molecular Tumor Microenvironment and Translational Biomarkers in Brain Metastases of Non-Small-Cell Lung Cancer
Jiexi Wen, Jie Zeng Yu, Catherine Liu, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 4, pp. 2044-2044
Open Access | Times Cited: 7
Circulating tumor DNA: from discovery to clinical application in breast cancer
Jiachi Xu, Hongyu Gao, Xinyu Guan, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 7
Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial
Solange Peters, Shirish M. Gadgeel, Tony Mok, et al.
Nature Medicine (2024) Vol. 30, Iss. 7, pp. 1923-1932
Open Access | Times Cited: 6
DNA liquid biopsy-based prediction of cancer-associated venous thromboembolism
Justin Jee, A. Rose Brannon, Rohan Kumar Singh, et al.
Nature Medicine (2024) Vol. 30, Iss. 9, pp. 2499-2507
Open Access | Times Cited: 6
Genetic and Genomic Testing for Prostate Cancer: Beyond DNA Repair
Cameron Herberts, Alexander W. Wyatt, Paul L. Nguyen, et al.
American Society of Clinical Oncology Educational Book (2023), Iss. 43
Closed Access | Times Cited: 14
Confirming size-exclusion chromatography as a clinically relevant extracellular vesicles separation method from 1mL plasma through a comprehensive comparison of methods
Stephen Robinson, Mark Samuels, William Jones, et al.
Deleted Journal (2024) Vol. 1, Iss. 1
Open Access | Times Cited: 5
Prognostic Value of Residual Circulating Tumor DNA in Metastatic Pancreatic Ductal Adenocarcinoma
Hongkyung Kim, Jinho Lee, Mi Ri Park, et al.
Annals of Laboratory Medicine (2025) Vol. 45, Iss. 2, pp. 199-208
Open Access
Multiple time points for detecting circulating tumor DNA to monitor the response to neoadjuvant therapy in breast cancer: a meta-analysis
Shuyi Niu, Tie Sun, Mozhi Wang, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Apports et limites de l’ADN tumoral circulant dans le cancer du sein
Nicolas Kiavué, Luc Cabel
Bulletin du Cancer (2025)
Open Access
The Prospectives and Limitations of Liquid Biopsy Utilization for Clinical Practice in Taiwan
Huei-Ying Li, C.L. Chang, Yu-Hsuan Yang, et al.
The Journal of Liquid Biopsy (2025) Vol. 7, pp. 100290-100290
Closed Access
Low-coverage whole genome sequencing of cell-free DNA to predict and track immunotherapy response in advanced non-small cell lung cancer
Florian Janke, M. Gasser, Arlou Kristina Angeles, et al.
Journal of Experimental & Clinical Cancer Research (2025) Vol. 44, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top